Obstacles to improving outcomes in the treatment of uveal melanoma

被引：19
作者：
Tsai, Katy K. [1 ]
Bollin, Kathryn B. [2 ]
Patel, Sapna P. [3 ]
机构：
[1] Univ Calif San Francisco, Cutaneous Oncol, Hellen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Scripps Clin, Div Hematol & Oncol, La Jolla, CA 92037 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA
来源：
CANCER | 2018年 / 124卷 / 13期
基金：
美国国家卫生研究院;
关键词：
barriers; challenges; outcomes; success; therapy; treatment; trials; uveal melanoma; INTRAARTERIAL HEPATIC FOTEMUSTINE; DEPENDENT PROBE AMPLIFICATION; GENE-EXPRESSION PROFILE; LIVER METASTASES; CHOROIDAL MELANOMA; DOUBLE-BLIND; PROGNOSTIC IMPLICATIONS; UNTREATED MELANOMA; COMPLETE RESECTION; TUMOR DIAMETER;
D O I：
10.1002/cncr.31284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The rate of advances in uveal melanoma has not kept pace with the rate of advances in cutaneous melanoma. Many patients lack access to or knowledge of specialty centers, and integrated multidisciplinary care between ophthalmology, radiation oncology, and medical oncology is far from the norm. This treatment isolation leads to limited communication about novel clinical trial opportunities. Clinical trials themselves are not widely available, and a lack of robust funding limits rapid and complete investigations. This review outlines the obstacles to success in uveal melanoma management and highlights strategies for overcoming these challenges. (C) 2018 American Cancer Society.
引用
收藏
页码：2693 / 2703
页数：11
相关论文
共 82 条
  • [51] Uveal Melanoma UK National Guidelines
    Nathan, P.
    Cohen, V.
    Coupland, S.
    Curtis, K.
    Damato, B.
    Evans, J.
    Fenwick, S.
    Kirkpatrick, L.
    Li, O.
    Marshall, E.
    McGuirk, K.
    Ottensmeier, C.
    Pearce, N.
    Salvi, S.
    Stedman, B.
    Szlosarek, P.
    Turnbull, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (16) : 2404 - 2412
  • [52] National Comprehensive Cancer Network, 2017, MEL
  • [53] National Health and Medical Research Council, OC PER MEL SUPPL DOC
  • [54] Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?
    Niederkorn, Jerry Y.
    [J]. FRONTIERS IN IMMUNOLOGY, 2012, 3
  • [55] Collaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma
    Onken, Michael D.
    Worley, Lori A.
    Char, Devron H.
    Augsburger, James J.
    Correa, Zelia M.
    Nudleman, Eric
    Aaberg, Thomas M., Jr.
    Altaweel, Michael M.
    Bardenstein, David S.
    Finger, Paul T.
    Gallie, Brenda L.
    Harocopos, George J.
    Hovland, Peter G.
    McGowan, Hugh D.
    Milman, Tatyana
    Mruthyunjaya, Prithvi
    Simpson, E. Rand
    Smith, Morton E.
    Wilson, David J.
    Wirostko, William J.
    Harbour, J. William
    [J]. OPHTHALMOLOGY, 2012, 119 (08) : 1596 - 1603
  • [56] Focus on cutaneous and uveal melanoma specificities
    Pandiani, Charlotte
    Beranger, Guillaume E.
    Leclerc, Justine
    Ballotti, Robert
    Bertolotto, Corine
    [J]. GENES & DEVELOPMENT, 2017, 31 (08) : 724 - 743
  • [57] The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with uveal melanoma (UM).
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Diab, Adi
    Amaria, Rodabe Navroze
    Davies, Michael A.
    Hwu, Patrick
    Tawbi, Hussein Abdul-Hassan
    Hwu, Wen-Jen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [58] Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients
    Peters, S
    Voelter, V
    Pampallona, S
    Popescu, R
    Gillet, M
    Bosshard, W
    Fiorentini, G
    Lotem, M
    Weitzen, R
    Keilholz, U
    Humblet, Y
    Piperno-Neumann, S
    Stupp, R
    Leyvraz, S
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (04) : 578 - 583
  • [59] A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ).
    Piperno-Neumann, Sophie
    Rodrigues, Manuel Jorge
    Servois, Vincent
    Pierron, Gaelle
    Gastaud, Lauris
    Negrier, Sylvie
    -Gabriel, Christine Levy
    Lumbroso, Livia
    Cassoux, Nathalie
    Bidard, Francois -Clement
    Michielin, Olivier
    Lacour, Jean -Philippe
    Durando, Xavier
    Mariani, Pascale
    Plancher, Corine
    Asselain, Bernard
    Armanet, Sebastien
    Mosseri, Veronique
    Desjardins, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [60] Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David
    Salama, April K.
    Taylor, Matthew
    Ott, Patrick A.
    Rollin, Linda M.
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    Hodi, F. Stephen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) : 2006 - 2017
123456789